Glembatumumab vedotin

Ott et al; ESMO 2016 Poster, October 2016
"A Phase 2 Study of Glembatumumab Vedotin (GV), an Antibody-Drug Conjugate (ADC) Targeting gpNMB, in Advanced Melanoma"
PDF Read More →

Halim et al; AACR 2016 Poster, April 2016
"Glycoprotein NMB (gpNMB) Overexpression is Prevalent in Human Cancers: Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, and Osteosarcoma"
PDF Read More →

Yardley et al; ASCO Breast Cancer Symposium 2015 Poster, September 2015
“gpNMB Expression Patterns in Breast Cancer (BC): Retrospective Evaluation of Tumor Tissue from the Phase 2 EMERGE Study”
PDF Read More →

Yardley et al; ASCO 2015 Poster, May 2015
“METRIC: A Randomized International Study of the Antibody-Drug Conjugate Glembatumumab Vedotin (GV or CDX-011) in Patients (pts) with Metastatic gpNMB-Overexpressing Triple-Negative Breast Cancer (TNBC)”
PDF Read More →

Yardley et al; Journal of Clinical Oncology, May 2015
"EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer"
Read More →

Yardley et al; SABCS 2013 Poster, December 2013
“A Pivotal, Multicenter, Randomized Study Evaluating the Novel Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011; CR011-vcMMAE) in Patients with Metastatic, Triple-negative, gpNMB Over-expressing Breast Cancer”
PDF Read More →

Yardley et al; SABCS 2012 Poster, December 2012
“A Randomized Phase II Study of the Antibody-drug Conjugate CDX-011 in Advanced GPNMB Overexpressing Breast Cancer: The EMERGE Study”
PDF Read More →

Hamid et al; ASCO 2010 Poster, June 2010
“Frequent Dosing and GPNMB Expression with CDX-011 (CRO11-vcMMAE), an Antibody-Drug Conjugate (ADC), in Patients with Advanced Melanoma”
PDF Read More →

Saleh et al; ASCO 2010 Poster, June 2010
“Correlation of GPNMB Expression with Outcome in Breast Cancer (BC) Patients Treated with the Antibody-Drug Conjugate (ADC), CDX-011 (CR011-vcMMAE)
PDF Read More →

Rose at al; Clinical Cancer Research, April 2010
“Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer”
Read More →

Burris et al; SABCS 2009 Poster, December 2009
“A Phase I/II Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer”
PDF Read More →

Peacock et al; ASCO 2009 Poster, June 2009
“A Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer”
PDF Read More →

Hwu et al; ASCO 2009 Poster, June 2009
“A Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate Targeting GPNMB in Patients with Advanced Melanoma”
PDF Read More →

Pollack et al; Cancer Chemotherapy and Pharmacology, March 2007
“Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate  (CR011-vcMMAE) targeting GPNMB”
Read More →

Tse at al; Clinical Cancer Research, February 2006
“CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma”
Read More →


Varlilumab

Sanborn et al; AACR 2016 Poster; April 2016
"Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"
PDF Read more → 

He et al; SITC 2015 Poster; November 2015
"The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"
PDF Read more → 

Ramakrishna et al; Journal for ImmunoTherapy of Cancer; August 2015
"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"
PDF Read more → PDF Supplemental data →

Thomas et al; AACR 2015 Poster; April 2015
"Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site "
PDF Read more →

Bullock et al; SITC 2014 Poster, November 2014
“Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity”
PDF Read More →

Infante et al; ASCO 2014 Poster, June 2014
“Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors”
PDF Read More →

Ansell et al; ASCO 2014 Poster, June 2014
“Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies”
PDF Read More →

Thomas et al; OncoImmunology, January 2014
“Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity”
PDF Read More →

Keler et al; SITC 2013 Poster, November 2013
“Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models”
PDF Read More →

Burris, et al; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

Ansell, Stephen; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

He et al; Journal of Immunology, September 2013
“Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice
PDF Read More →

Sundarapandiyan et al; AACR 2013 Poster, April 2013
“Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb”
PDF Read More →

Vitale et al; Clinical Cancer Research, May 2012
“Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia”
Read More →

He et al; AACR 2012 Poster, April 2012
“Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model”
PDF Read More →

He et al; ASH 2011 Poster, December 2011
“Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms”
PDF Read More →

Thomas et al; AACR 2011 Poster, April 2011
“Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model”
PDF Read More →

He et al; AACR 2010 Poster, April 2010
“Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential”
PDF Read More →


CDX-0158 (formerly KTN0158)

Garton et al; Molecular Cancer Therapeutics, January 2017
"Anti-KIT Monoclonal Antibody Treatment Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression"
Read More →

London et al; Clinical Cancer Research, November 2016
"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells"
Read More →

Stahl et al; Immunotherapy, June 2016
"Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors"
Read More →

Garton et al; AACR 2016 Poster, April 2016
"Inhibition of KIT In Vivo Modifies Immune Cell Populations to Improve The Efficacy of Checkpoint Inhibitors in Syngeneic Mouse Tumor Models"
PDF Read More →

LaVallee et al; Critical Reviews in OncoGenesis, 2015
"Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders"
Read More →

London et al; AACR-NCI-EORTC 2015 Poster, November 2015
"KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Antitumor Activity in Dogs with Mast Cell Tumors"
PDF Read More →

London et al; ESMO 2015 Poster, September 2015
"KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Antitumor Activity in Dogs with Mast Cell Tumors"
PDF Read More →

Mandel et al; ACAAI 2014 Poster, November 2014
"KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Reduces Airway Eosinophilia in a Feline Model of Allergic Asthma"
PDF Read More →

Gedrich et al; Neurofibromatosis Conference 2014 Poster, June 2014
"Regulation of Mast Cell Activity by KTN0158, a Humanized anti-KIT Monoclonal Antibody"
PDF Read More →


CDX-3379 (formerly KTN3379)

LaVallee et al; Critical Reviews in OncoGenesis, 2015
"Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders"
Read More →


CDX-1401

Bhardwaj et al; ASCO 2016 Poster, June 2016
"A Phase 2, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with CDX-301, a Recombinant Human Flt3 Ligand"
PDF Read More →

Halim et al; AACR 2016 Poster, April 2016
"IHC and RT-PCR Assays for Detection of Cancer Antigen NY-ESO-1 in Human Tissues"
PDF Read More →

Dhodapkar et al; Science Translational Medicine, April 2014 
“Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205”
 Read More →

Dhodapkar et al; SITC 2012 Poster, October 2012
“A Phase 1 Trial of a Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 in Combination with Toll-like Receptor Agonists”
PDF Read More →

Tsuji et al; The Journal of Immunology, January 2011
“Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity”
Read More →

Dhodapkar et al; iSBTc 2010 Poster, October 2010
“Early Development of CDX-1401, A Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, in Combination with Toll-like Receptor Agonists”
PDF Read More →


CDX-301

Marron et al; AACR 2016 Poster, April 2016
"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"
PDF Read More →

Jaglowski et al; ASBMT 2016 Poster, February 2016
"Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"
PDF Read More →

Anandasabapathy et al; Bone Marrow Transplantation, April 2015
“Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers”
Read More →

Yellin et al; BMT 2013 Presentation, February 2013
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”  
PDF Read More →

Anandasabapathy et al; ASH 2012 Poster, December 2012
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”
PDF Read More →


CDX-014

Thomas et al; Molecular Cancer Therapeutics, September 2016
“Development of a Novel Antibody-drug Conjugate for the Potential Treatment of Ovarian, Lung and Renal Cell Carcinoma Expressing TIM-1”
Read More →

Thomas et al; AACR 2014 Poster, April 2014
“Development of an Antibody-drug Conjugate Targeting TIM-1 for the Treatment of Ovarian and Renal Cell Carcinoma”  
PDF Read More →


CDX-1140

He et al; ASH 2016 Poster, December 2016
"CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity"
PDF Read More →

Vitale et al; SITC 2016 Poster, November 2016
“Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy”
PDF Read More →

Vitale et al; AACR 2016 Poster, April 2016
“Development and characterization of novel CD40 antibody agonists for cancer immunotherapy”
PDF Read More →


TAM Program

LaVallee et al; Critical Reviews in Oncogenesis, 2015
"Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders"
Read More →

This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.